MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6251
-0.0519
-7.67%
After Hours: 0.6590 +0.0339 +5.42% 19:36 05/18 EDT
OPEN
0.7100
PREV CLOSE
0.6770
HIGH
0.7100
LOW
0.6200
VOLUME
1.24M
TURNOVER
183.06K
52 WEEK HIGH
7.80
52 WEEK LOW
0.6200
MARKET CAP
13.74M
P/E (TTM)
-0.3791
1D
5D
1M
3M
1Y
5Y
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Benzinga · 1d ago
Recap: Aprea Therapeutics Q1 Earnings
  Aprea Therapeutics (NASDAQ:APRE) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 2d ago
Aprea Therapeutics GAAP EPS of -$0.36 beats by $0.02
Aprea Therapeutics press release (NASDAQ:APRE): Q1 GAAP EPS of -$0.36 beats by $0.02. As of March 31, 2022, the Company had $47.6 million of cash and cash equivalents compared to $53.1 million of cash
Seekingalpha · 2d ago
Aprea Shares Update On Its Eprenetapopt Program In Various Blood Cancer Settings
Aprea Therapeutics Inc (NASDAQ: APRE) can 
Benzinga · 03/21 08:59
FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Lymphoid Malignancies
 
Benzinga · 03/21 08:28
FDA Lifts Clinical Hold On Aprea's Relapsed/Refractory Blood Cancer Studies
Aprea Therapeutics Inc (NASDAQ: APRE) can resume testing its eprenetapopt after a string of clinical holds on the therapy in August 2021.  The Company plans to study the drug in new trials across various myeloid and lymphoid malignancies. 
Benzinga · 03/16 18:41
--HC Wainwright Adjusts Aprea Therapeutics' Price Target to $2 From $4, Maintains Neutral Rating
MT Newswires · 03/16 08:25
--RBC Trims Price Target on Aprea Therapeutics to $4 From $5, Maintains Sector Perform Rating, Speculative Risk Qualifier
MT Newswires · 03/16 07:56
More
No Data
Learn about the latest financial forecast of APRE. Analyze the recent business situations of Aprea Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average APRE stock price target is 3.000 with a high estimate of 4.000 and a low estimate of 2.000.
High4.000
Average3.000
Low2.000
Current 0.6251
EPS
Actual
Estimate
-0.38-0.29-0.19-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 58
Institutional Holdings: 3.69M
% Owned: 16.79%
Shares Outstanding: 21.97M
TypeInstitutionsShares
Increased
9
273.36K
New
12
880.15K
Decreased
11
485.17K
Sold Out
9
2.02M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.24%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Chairman/President/Chief Executive Officer/Director
Christian Schade
Chief Financial Officer/Senior Vice President/Secretary
Scott Coiante
Senior Vice President/Chief Scientific Officer
Lars Abrahmsen
Senior Vice President
Eyal Attar
Senior Vice President
Gregory Korbel
Lead Director/Independent Director
John Henneman
Independent Director
Michael Kelly
Independent Director
Fouad Namouni
Independent Director
Richard Peters
Independent Director
Bernd Seizinger
No Data
No Data
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The Company's lead product, eprenetapopt (APR-246), is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator that is being developed in an oral dosage form.

Webull offers kinds of Aprea Therapeutics Inc stock information, including NASDAQ:APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.